<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Psychiatry: Mild Cognitive Impairment Topic Collection</title>
    <link>http://archpsyc.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Mon, 31 Dec 2012 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 01 Jan 2013 00:49:00 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@archpsyc.jamanetwork.com</managingEditor>
    <webMaster>webmaster@archpsyc.jamanetwork.com</webMaster>
    <item>
      <title>Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia</title>
      <link>http://archpsyc.jamanetwork.com/article.aspx?articleID=1107443</link>
      <pubDate>Sun, 01 Jan 2012 00:00:00 GMT</pubDate>
      <author>Buchhave P, Minthon L, Zetterberg H, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Context&lt;/div&gt;Early detection of prodromal Alzheimer disease (AD) is important because new disease-modifying therapies are most likely to be effective when initiated during the early stages of disease.&lt;div class="boxTitle"&gt;Objectives&lt;/div&gt;To assess the ability of the cerebrospinal fluid (CSF) biomarkers total tau (T-tau), phosphorylated tau (P-tau), andβ-amyloid 1-42 (Aβ42) to predict future development of AD dementia within 9.2 years in patients with mild cognitive impairment (MCI) and to compare CSF biomarkers between early and late converters to AD.&lt;div class="boxTitle"&gt;Design&lt;/div&gt;A clinical study with a median follow-up of 9.2 years (range, 4.1-11.8 years).&lt;div class="boxTitle"&gt;Setting&lt;/div&gt;Memory disorder clinic.&lt;div class="boxTitle"&gt;Patients&lt;/div&gt;A total of 137 patients with MCI who underwent lumbar puncture at baseline.&lt;div class="boxTitle"&gt;Main Outcome Measure&lt;/div&gt;Conversion to AD dementia.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;During follow-up, 72 patients (53.7%) developed AD and 21 (15.7%) progressed to other forms of dementia. At baseline, CSF Aβ42 levels were reduced and T-tau and P-tau levels were elevated in patients who converted to AD during follow-up compared with nonconverters (P &lt; .001). Baseline CSF Aβ42 levels were equally reduced in patients with MCI who converted to AD within 0 to 5 years (early converters) compared with those who converted between 5 and 10 years (late converters). However, CSF T-tau and P-tau levels were significantly higher in early converters vs late converters. A baseline Aβ42:P-tau ratio predicted the development of AD within 9.2 years with a sensitivity of 88%, specificity of 90%, positive predictive value of 91%, and negative predictive value of 86%.&lt;div class="boxTitle"&gt;Conclusions&lt;/div&gt;Approximately 90% of patients with MCI and pathologic CSF biomarker levels at baseline develop AD within 9 to 10 years. Levels of Aβ42 are already fully decreased at least 5 to 10 years before conversion to AD dementia, whereas T-tau and P-tau seem to be later markers. These results provide direct support in humans for the hypothesis that altered Aβ metabolism precedes tau-related pathology and neuronal degeneration.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">69</prism:volume>
      <prism:number xmlns:prism="prism">1</prism:number>
      <prism:startingPage xmlns:prism="prism">98</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">06</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/archgenpsychiatry.2011.155</prism:doi>
      <guid>http://archpsyc.jamanetwork.com/article.aspx?articleID=1107443</guid>
    </item>
  </channel>
</rss>